08:00 , Feb 23, 2015 |  BioCentury  |  Emerging Company Profile

Eyeing new antibiotics

Traditional antibiotics kill bacteria by inhibiting protein, DNA, or cell wall synthesis but require multiplying cells to be effective. SinSa Laboratories Inc.'s peptide antibiotics kill slow- and fast-growing bacteria by direct disruption of the cell...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Lytix, Pharmasum Therapeutics neurology news

Infectious disease and cancer company Lytix spun out Pharmasum to develop PST-900, a dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitor to treat dementia. Pharmasum hopes to move the discovery-stage compound into the clinic...
07:00 , Jun 6, 2011 |  BC Week In Review  |  Clinical News

Lytixar: Phase I/IIa data

A placebo-controlled, dose-escalation, Swedish Phase I/IIa trial showed that Lytixar was well tolerated, with negligible systemic uptake. The company said the study demonstrated proof of concept for Lytixar in decolonizing bacteria. Lytix Biopharma A/S, Tromso,...
07:00 , Jun 6, 2011 |  BC Week In Review  |  Clinical News

Lytixar: Phase I/IIa data

A placebo-controlled, Hungarian Phase I/IIa trial showed that Lytixar was well tolerated, with negligible systemic uptake. Lytix Biopharma A/S, Tromso, Norway   Product: Lytixar ( LTX-109)   Business: Infectious   Molecular target: NA   Description: Topical synthetic antimicrobial...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Clinical News

Lytixar: Phase IIa start

This half, Lytix will begin a double-blind, placebo-controlled, Hungarian Phase IIa trial to evaluate 1, 2 and 5% topical LTX-109 in 24 patients. Lytix Biopharma A/S, Tromso, Norway   Product: Lytixar ( LTX-109)   Business: Infectious...
07:00 , May 31, 2010 |  BC Week In Review  |  Clinical News

Lytixar: Phase I/IIa start

Next half, Lytix will begin a placebo-controlled, dose-escalation, Swedish Phase I/IIa trial to evaluate Lytixar in patients who are nasal carriers of MRSA. Lytix Biopharma A/S, Tromso, Norway   Product: Lytixar ( LTX-109)   Business: Infectious...
08:00 , Jan 26, 2009 |  BioCentury  |  Finance

Ebb & Flow

Taiwan's Taigen Biotechnology was able to raise $37 million in a series C round last week, but at a steep discount that helps explain why it's sometimes better to be an early stage investor. The...
01:48 , Jan 23, 2009 |  BC Extra  |  Financial News

Lytix raises $10.6 million

Lytix (Tromso, Norway) raised NOK73 million ($10.6 million) in a private round through an undisclosed group of new and existing investors. SpareBank Nord-Norge advised Lytix. The company plans to begin Phase I/II testing of two...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

Lytix Biopharma AS preclinical data

In mice, topical LTX-109 killed Staphylococcus aureus and Streptococcus pyogenes after 1 day of treatment. The synthetic antimicrobial peptidomimetic also had activity against Pseudomonoas aeruginosa isolates that were resistant to ceftazidime, ciprofloxacin, imipenem and gentamicin....